James Powell

Novo Nordisk における VP, RNAi CMC and Boulder Site Head

スピーカー

James Powell is the VP, RNAi CMC and Boulder Site Head at Novo Nordisk. With 36 years of experience in manufacturing and development of oligonucleotide therapeutics, he initially held positions in process chemistry, manufacturing, and operations management at Synthecell, La Jolla Pharmaceuticals, Codon Pharmaceuticals, and Ribozyme Pharmaceuticals. In 2002, he founded Transgemomics Nucleic Acid API division, later sold to Eyetech then Agilent, where he served as General Manager for five years. Most recently, he was the SVP of CMC at Dicerna Pharmaceuticals before its acquisition by Novo Nordisk in 2021.